Press Detail

News: Biotest AG: Biotest AG opens seventh plasma collection centre in Hungary

News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest AG opens seventh plasma collection centre in Hungary

16.05.2017 / 07:00
The issuer is solely responsible for the content of this announcement.


Biotest AG opens seventh plasma collection centre in Hungary

- 15 plasma collection centres in Europe and

- 22 in the US to ensure long-term plasma supply

Dreieich, 16 May 2017. Biotest received an operating permit for its seventh
plasma collection centre in Hungary from the country's national public
health authority OTH. The centre is located in the second largest Hungarian
city of Debrecen in the eastern part of the country and is one of Europe's
most modern ones. It provides space for up to 32 donation chairs. Thus, the
company is further expanding its plasma collection capacity and is
safeguarding the plasma supply to future growth.

The first plasma collection centre in Budapest was opened in 2009 by
Plazmaszolgálat Kft., a 100% subsidiary of Biotest AG. "We are very pleased
about the opening of another donor centre in Hungary. In Debrecen, we create
more than 25 highly qualified jobs and ensure the supply of plasma for life
saving drugs", stated Dr Martin Reinecke, Senior Vice President Plasma
Alliances and Protein Supply of Biotest AG.

The collected plasma is processed only by Biotest AG at Dreieich, Germany.
Regular audits in Hungary ensure that the strict legal and internal quality
requirements are met.

About human blood plasma
Human blood plasma is a raw material used to produce plasma derived
products, which are used to treat various illnesses of the immune system,
the blood system, as well as in emergency medicine. Biotest ranks as one of
the world's sixth largest plasma protein product manufacturing groups.
Biotest is one of the world's six largest manufacturers of plasma protein

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406

PR contact
Dirk Neumüller
phone: +49-6103-801-269

Biotest AG, Landsteinerstr. 5, 63303 Dreieich,

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,


This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.

16.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange

End of News DGAP News Service

573819 16.05.2017